etoposide has been researched along with Alopecia in 82 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 25 (30.49) | 18.7374 |
1990's | 29 (35.37) | 18.2507 |
2000's | 20 (24.39) | 29.6817 |
2010's | 8 (9.76) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Arnold, R; Djabali, K; Henriques, G; Liu, C | 1 |
Aerts, JG; Gras, J; Hoogsteden, H; Pouw, E; Pronk, T; Salomé, J; Schmitz, PI; Surmont, V; Tan, KY; van Klaveren, RJ; Vernhout, R | 1 |
Aldabbagh, K; Fabbro, M; Jacot, W; Pouderoux, S; Poujol, S; Roca, L; Romieu, G | 1 |
Fanti, PA; Misciali, C; Miteva, M; Romanelli, P; Tosti, A; Vincenzi, C | 1 |
Amini, S; Elgart, G; Jimenez, JJ; Mauro, LM; Schachner, LA; Simon, J; Wikramanayake, TC | 1 |
Jimenez, JJ; Mauro, LM; Nouri, K; Perez, CI; Schachner, LA; Villasante, AC; Wikramanayake, TC | 1 |
Fu, K; Hao, XS; Hou, Y; Li, LF; Li, W; Liu, XM; Qian, ZZ; Qiu, LH; Wang, HQ; Zhang, HL; Zhou, SY | 1 |
Baptista, AM; Belfort, P | 1 |
Li, AW; Liu, JM; Luo, J; Wu, FY; Zheng, D | 1 |
Chamberlain, MC | 2 |
Acquati, M; Ardizzoia, A; Casartelli, C; Fagnani, D; Fusco, O; Giordano, M; Malugani, F; Quattrone, A; Scanni, A; Tagliabue, P; Vergani, C; Visini, M | 1 |
Takahata, K; Tsuruki, T; Yoshikawa, M | 3 |
Ito, A; Takaha, K; Tsuruki, T; Yoshikawa, M | 1 |
Aimé, P; Coninx, P; Legros, M; Mérol, JC; Moutel, K; Nasca, S; Prévost, A; Roger-Liautaud, F | 1 |
Tsuruki, T; Yoshikawa, M | 2 |
Alberts, SR; Erlichman, C; Furth, A; Lathia, CD; Molina, JR; Reid, JM; Safgren, SL; Sloan, JA | 1 |
Fukasawa, K; Izumi, M; Kamiyama, J; Kawa, S; Maruyama, S; Nikaido, T; Sakai, T; Sukenaga, Y; Takahara, Y; Wakada, M; Watanabe, N; Yogosawa, S; Yokoyama, H; Yoshizawa, K; Zhang, H | 1 |
Bo, LJ; Chen, YH; Jin, XP; Liang, AB; Liu, B; Wang, F | 1 |
Asoh, S; Mori, T; Nakashima-Kamimura, N; Nishimaki, K; Ohta, S | 1 |
Aisner, J; Wiernik, PH | 1 |
Canellos, GP; Garnick, MB; Lederman, GS; Richie, JP | 1 |
Choo, YC; Ma, HK; Wong, LC | 1 |
Hattori, K; Ito, K; Kobayashi, S; Nakamura, S; Nakanishi, J; Ohtake, S; Yoshida, T | 1 |
Demitrish, M; Duffin, H; Enochs, K; Groshko, G; Lockhard, C; Maniscalco-Greb, E; Vaughn, CB | 1 |
Hussein, AM; Peters, WP; Stuart, A | 1 |
Albeck, M; Bruderman, I; Catane, R; Kalechman, Y; Kaufman, B; Shani, A; Shapira, J; Sredni, B; Tichler, T | 1 |
Allen, SL; Behr, J; Budman, DR; Hock, K; Igwemezie, LN; Kaul, S; Kolitz, J; Lichtman, S; Schulman, P; Vinciguerra, V | 1 |
Ashley, S; Holborn, J; Jones, AL; Smith, IE | 1 |
Fukuda, H; Hosokawa, K; Kondo, H; Ohtsu, A; Saito, D; Shimada, Y; Shirao, K; Yamao, T; Yoshida, S | 1 |
Kamijima, S; Kato, Y; Kobayashi, H; Kuwahara, M; Mihara, H; Nagasaka, T; Oguri, T; Takeda, H | 1 |
Asbury, RF; Boros, L; Chang, AY; Garrow, GC; Hui, L | 1 |
Chen, S; Lee, BC; Miller, AA; Molthrop, DC; Robert, F; Wheeler, RH | 1 |
Copplestone, A; Couteaux, ME; Deconinck, E; Economopoulos, T; Fenaux, P; Foussard, C; Guerci, A; Hecquet, B; Mahé, B; Michaux, JL; Mufti, G; Oscier, D; Pegourié, B; Resegotti, L; Stoppa, AM; Voglova, V; Wattel, E | 1 |
Akbulut, H; Cay, F; Demirkazik, A; Dinçol, D; Içli, F; Karaoguz, H | 1 |
Inoda, H; Kutsuki, M; Mori, M; Nishikawa, M; Nishimura, K; Takigami, K; Yamaguchi, Y; Yamamoto, C; Yoshitake, K | 1 |
Bergman, B; Chemaissani, A; Dornoff, W; Drings, P; Kellokumpu-Lehtinen, P; Liippo, K; Manegold, C; Mattson, K; Ricci, S; Sederholm, C; Stahel, P; ten Bokkel Huinink, W; van Walree, N; von Pawel, J; Wagenius, G | 1 |
Pienta, KJ; Smith, DC | 1 |
Hara, N; Hirose, N; Inutsuka, S; Kanegae, H; Kawarada, Y; Kurita, Y; Miyazaki, M; Miyazaki, N; Nakanishi, Y; Ninomiya, K; Ogata, K; Ohgushi, O; Yamazaki, H | 1 |
Chen, PM; Chiou, TJ; Fan, FS; Hsieh, RK; Liu, JH; Tung, SL; Wang, WS; Yen, CC | 1 |
Chao, Y; Chen, LT; Chen, YM; Chiou, TC; Hsieh, RK; Liu, JM; Liu, SM; Tiu, CM; Whang-Peng, J; Wu, HW | 1 |
Adachi, I; Inaji, H; Kanda, K; Kikkawa, N; Koyama, H; Miura, S; Nakao, K; Shiba, E; Tajima, T; Takai, S; Tamura, K; Toge, T; Yoshida, M | 1 |
Benjamin, RS; Gano, J; Gianan, MA; Jaffe, N; Jia, SF; Kleinerman, ES; Papadopoulos, NE; Patel, S; Raymond, AK; Rodriguez, C; Worth, LL | 1 |
Fujii, S; Hasegawa, K; Hirabayasi, K; Ikeda, M; Izumi, R; Kono, I; Kudo, R; Niitani, H; Nishiya, I; Noda, K; Ochiai, K; Ogita, Y; Okada, H; Ozaki, M; Saito, T; Sugimori, H; Suzuoki, Y; Tanaka, K; Terashima, Y; Tomoda, Y; Umesaki, N; Yajima, A; Yakushiji, M; Yamabe, T; Yamamoto, T | 1 |
Asamoto, H; Furuse, K; Iwami, F; Kawahara, M; Kuba, M; Saijo, N; Shimoyama, M; Tamura, T | 1 |
Hatae, M; Hiura, M; Hoshiai, H; Ikeda, M; Izumi, R; Noda, K; Ogita, Y; Okada, H; Ozaki, M; Ozawa, M; Tamaya, T; Tanaka, K; Yamabe, T | 1 |
Astoul, P; Boutin, C; Gouvernet, J; Irisson, M; Juin, P; Pignon, T; Ruggieri, S | 1 |
Tada, M; Takahata, K; Tamaki, T; Yazawa, K | 1 |
Bamias, A; Katsimbri, P; Pavlidis, N | 1 |
Bilgrami, S; Bona, RD; Edwards, RL; Feingold, JM; Kapur, D; Khan, AM; Rodriguez-Pinero, F; Tutschka, PJ | 1 |
Benson, BG; Bramson, HN; Chapman, DE; Davis, ST; Dickerson, SH; Dold, KM; Eberwein, DJ; Edelstein, M; Frye, SV; Gampe, RT; Griffin, RJ; Harris, PA; Hassell, AM; Holmes, WD; Hunter, RN; Knick, VB; Kuyper, LF; Lackey, K; Lovejoy, B; Luzzio, MJ; Murray, D; Parker, P; Rocque, WJ; Shewchuk, L; Veal, JM; Walker, DH | 1 |
Marx, J | 1 |
Hosaka, Y; Kato, K; Mochizuki, H; Muramatsu, H; Nagata, S; Nakamura, N; Nakayama, K; Ohmori, Y; Saitoh, F; Takiguchi, K; Tsuda, T | 1 |
Christodoulou, C; Efstathiou, E; Klouvas, G; Papazachariou, E; Plyta, M; Skarlos, DV; Zervakis, D | 1 |
Bunn, PA; Ihde, DC; Radice, PA | 1 |
Decker, DG; Edmonson, JH; Jorgensen, EO; Malkasian, GD; Webb, MJ | 1 |
Jimenez, JJ; Yunis, AA | 1 |
Bernacer, B; Candel, MT; Garcia, J; Jimeno, J; Villar-Grimalt, A | 1 |
Achterrath, W; Eiermann, W; Hepp, H; Lenaz, L | 1 |
Chasen, MR; Falkson, G; Falkson, HC | 1 |
Hurukawa, H; Iwanaga, T; Numata, N; Ohshiba, S; Ohta, J; Ohtani, T; Okazima, K; Orino, M; Taguchi, T; Yamada, S | 1 |
de Góes, GM; Simon, SD; Srougi, M | 1 |
Bungo, M; Fujita, J; Futami, H; Hashimoto, Y; Hata, Y; Irino, S; Iuchi, Y; Kamei, M; Nakamura, H; Yamaji, Y | 1 |
Achterrath, W; Meyer, D; Nagel, GA; Rauschning, W; Wander, HE | 1 |
Boossy, J; Focan, C; Schallier, D; Vandermoten, G | 1 |
Kimura, K; Niitani, H | 1 |
Furuse, K | 1 |
Hara, K; Kado, M; Kanda, T; Matsui, Y; Oshima, S; Shima, K; Shimokata, K; Takenaka, S | 1 |
Hiraga, Y; Ito, T; Konno, K; Nagahama, F; Nakabayashi, T; Nakai, Y; Oizumi, K; Sato, M; Takebe, K; Tamura, M | 1 |
Allan, NC; Dawson, AA; Leonard, RC; Lucraft, HH; McGillivray, JB; Parker, AC; Prescott, RJ; Proctor, SJ | 1 |
Bishop, JF; Cobcroft, R; Dodds, A; Joshua, DE; Kronenberg, H; Lowenthal, RM; Manoharan, A; Whiteside, MG; Wolf, M | 1 |
De Lena, M; Lorusso, V; Romito, S | 1 |
Suzuki, K | 1 |
Dent, DM; Hayes, M; Jacobs, P; King, HS | 1 |
Bajetta, E; Bonadonna, G; Buzzoni, R; Nava, M; Vaglini, M; Viviani, S | 1 |
Kimura, K; Yamada, K; Yoshida, T | 1 |
Ito, K; Kobayashi, K; Matsuda, T; Nakagoshi, T; Nakamura, E; Nakamura, S; Nakanishi, J; Natori, K; Ohtake, S; Yoshida, T | 1 |
Felman, IE; Gala, KV; Grunberg, SM; Johnson, KB; Owens, JC | 1 |
31 trial(s) available for etoposide and Alopecia
Article | Year |
---|---|
Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study.
Topics: Administration, Oral; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Etoposide; Female; Humans; Kaplan-Meier Estimate; Leucovorin; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Tegafur; Uracil | 2009 |
Salvage chemotherapy for recurrent spinal cord ependymona.
Topics: Administration, Oral; Adult; Alopecia; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Drug Administration Schedule; Ependymoma; Etoposide; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Spinal Cord Neoplasms; Thrombocytopenia; Treatment Outcome; Weight Loss | 2002 |
Second line therapy with weekly low-dose docetaxel for pretreated non-small-cell lung carcinoma patients: a multicenter Italian phase II study.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Esophagitis; Etoposide; Female; Follow-Up Studies; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neurotoxicity Syndromes; Premedication; Remission Induction; Stomatitis; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
A randomized trial between two neoadjuvant chemotherapy protocols: CDDP + 5-FU versus CDDP + VP16 in advanced cancer of the head and neck.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; Etoposide; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Survival Analysis; Treatment Outcome; Vomiting | 2005 |
A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biphenyl Compounds; Carboplatin; Cohort Studies; Colonic Neoplasms; Enzyme Inhibitors; Etoposide; Female; Humans; Male; Matrix Metalloproteinase Inhibitors; Melanoma; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Neutropenia; Organic Chemicals; Phenylbutyrates; Thrombocytopenia; Thymoma; Treatment Outcome; Vomiting | 2005 |
[Phase II study of etoposide (NK 171) in advanced hematological malignancies].
Topics: Administration, Oral; Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Infusions, Parenteral; Leukemia; Leukopenia; Lymphoma; Male; Middle Aged; Nausea; Podophyllotoxin; Prednisolone; Thrombocytosis; Vincristine | 1984 |
Bone marrow-sparing and prevention of alopecia by AS101 in non-small-cell lung cancer patients treated with carboplatin and etoposide.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Non-Small-Cell Lung; Colony-Stimulating Factors; Ethylenes; Etoposide; Female; Humans; Interleukin-1; Interleukin-6; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prospective Studies; Remission Induction; Thrombocytopenia | 1995 |
Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors.
Topics: Adult; Aged; Alopecia; Chromatography, High Pressure Liquid; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Half-Life; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Organophosphorus Compounds; Prodrugs; Regression Analysis; Solubility; Vomiting | 1994 |
CVM versus ACE in the treatment of small cell lung cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Infant, Newborn; Infections; Leukopenia; Lung Neoplasms; Male; Methotrexate; Middle Aged; Thrombocytopenia; Treatment Outcome; Vinblastine | 1993 |
An early phase II study of etoposide (VP-16) in advanced gastric cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Adult; Aged; Alopecia; Anemia; Antineoplastic Agents, Phytogenic; Carcinoma, Signet Ring Cell; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Stomach Neoplasms | 1996 |
Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Creatinine; Etoposide; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infusion Pumps; Infusions, Intravenous; Male; Middle Aged; Mouth Mucosa; Neoplasms; Statistics, Nonparametric; Stomatitis | 1996 |
A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group.
Topics: Adult; Aged; Alopecia; Blood Cell Count; Cross-Over Studies; Etoposide; Female; Humans; Hydroxyurea; Karyotyping; Leukemia, Myelomonocytic, Chronic; Life Tables; Male; Middle Aged; Prognosis; Risk Factors; Splenomegaly; Survival Analysis; Treatment Outcome | 1996 |
Recurrent cerebellar gliomas: salvage therapy with oral etoposide.
Topics: Adolescent; Alopecia; Antineoplastic Agents, Phytogenic; Astrocytoma; Cerebellar Neoplasms; Child; Child, Preschool; Diarrhea; Etoposide; Female; Humans; Male; Neoplasm Recurrence, Local; Salvage Therapy; Survival Analysis | 1997 |
Phase II study of a modified combination of etoposide, doxorubicin, and cisplatin for patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Leukopenia; Male; Middle Aged; Nausea; Stomach Neoplasms; Survival Analysis; Vomiting | 1997 |
[CPE chemotherapy for tongue carcinoma--clinical effects and side effects].
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Male; Middle Aged; Nausea; Peplomycin; Tongue Neoplasms; Vomiting | 1997 |
A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Ribonucleotide Reductases; Treatment Outcome; Vomiting | 1997 |
Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Alopecia; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; DNA Replication; DNA, Neoplasm; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Estramustine; Etoposide; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Microtubules; Nuclear Matrix; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Rats; Remission Induction; Tumor Cells, Cultured | 1997 |
Phase II trial of combination chemotherapy with cisplatin, carboplatin and etoposide in stage IIIB and IV small-cell lung cancer. Fukuoka Lung Cancer Study Group.
Topics: Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Survival Rate; Treatment Outcome; Vomiting | 1998 |
Phase II study of the modified regimen of etoposide, leucovorin and 5-fluorouracil for patients with advanced gastric cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration Schedule; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Leukopenia; Levoleucovorin; Male; Middle Aged; Prognosis; Stomach Neoplasms; Survival Analysis | 1998 |
[Results of clinical study with epirubicin hydrochloride injectable solution and cyclophosphamide in breast cancer].
Topics: Administration, Oral; Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Middle Aged; Nausea; Receptors, Estrogen; Vomiting | 1998 |
Phase II study of recombinant interleukin 1alpha and etoposide in patients with relapsed osteosarcoma.
Topics: Adolescent; Adult; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Neoplasms; Capillary Leak Syndrome; Combined Modality Therapy; Cytokines; Drug Synergism; Etoposide; Feasibility Studies; Female; Femoral Neoplasms; Fever; Fibrosis; Gastrointestinal Diseases; Humans; Hypotension; Immunologic Factors; Interleukin-1; Lung Neoplasms; Male; Neutropenia; Osteosarcoma; Recombinant Proteins; Remission Induction; Respiration Disorders; Salvage Therapy; Treatment Outcome | 1997 |
[Early phase II trial of oral etoposide administered for 21 consecutive days in patients with cervical or ovarian cancer. ETP 21 Study Group--Cervical-Ovarian Cancer Group].
Topics: Administration, Oral; Adult; Aged; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Etoposide; Female; Humans; Leukopenia; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Uterine Cervical Neoplasms | 1998 |
Cisplatin plus oral etoposide in the treatment of patients with advanced small cell lung cancer. Japan Clinical Oncology Group.
Topics: Administration, Oral; Adult; Aged; Alopecia; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Thrombocytopenia; Vomiting | 1998 |
[Late phase II trial of oral etoposide administered for 21 consecutive days in patients with cervical cancer. ETP 21 Study Group--Cervical Cancer Group].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Drug Administration Schedule; Etoposide; Female; Humans; Middle Aged; Nausea; Uterine Cervical Neoplasms; Vomiting | 1998 |
Alternating chemotherapy and accelerated split-course irradiation in locally advanced nonsmall cell lung carcinoma.
Topics: Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease Progression; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Radiotherapy; Survival Analysis; Treatment Outcome; Vomiting, Anticipatory | 1999 |
Prevention of chemotherapy-induced alopecia using an effective scalp cooling system.
Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cryotherapy; Docetaxel; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Scalp; Taxoids | 2000 |
Effectiveness of the MSC cold cap system in the prevention of chemotherapy-induced alopecia.
Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Hypothermia, Induced; Ifosfamide; Male; Middle Aged; Neoplasms; Paclitaxel; Scalp; Severity of Illness Index; Treatment Outcome | 2002 |
Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
Topics: Alopecia; Carcinoma, Small Cell; Clinical Trials as Topic; Drug Evaluation; Etoposide; Humans; Leukemia; Leukopenia; Lung Neoplasms; Lymphoma; Podophyllotoxin; Teniposide | 1979 |
[Combination chemotherapy with etoposide, ADM, and CDDP (EAP) for advanced gastric cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Male; Middle Aged; Stomach Neoplasms | 1990 |
VP-16-213 in the treatment of stage III and IV diffuse large cell lymphoma.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Leukopenia; Lymphoma; Male; Middle Aged; Podophyllotoxin; Prognosis; Prospective Studies; Random Allocation | 1985 |
Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Etoposide; Female; Humans; Leukopenia; Lomustine; Male; Melanoma; Middle Aged; Nausea; Neoplasm Metastasis; Prospective Studies; Random Allocation; Skin Neoplasms; Thrombocytopenia; Vindesine; Vomiting | 1985 |
51 other study(ies) available for etoposide and Alopecia
Article | Year |
---|---|
Inhibition of JAK-STAT Signaling with Baricitinib Reduces Inflammation and Improves Cellular Homeostasis in Progeria Cells.
Topics: Adenosine Triphosphate; Alopecia; Arthritis; Autophagy; Azetidines; Blotting, Western; Cell Cycle; Cells, Cultured; Cellular Senescence; Child; Child, Preschool; Data Mining; Etoposide; Female; Humans; Immunohistochemistry; Inflammation; Janus Kinase 1; Janus Kinase 2; Lamin Type A; Lipodystrophy; Male; Mutation; Progeria; Purines; Pyrazoles; Reactive Oxygen Species; STAT1 Transcription Factor; STAT3 Transcription Factor; Sulfonamides; Vascular Diseases | 2019 |
Etoposide, mitomycin, and methotrexate combination in heavily treated breast cancer: a retrospective study.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Etoposide; Female; Humans; Methotrexate; Middle Aged; Mitomycin; Retrospective Studies; Survival Rate | 2012 |
Permanent alopecia after systemic chemotherapy: a clinicopathological study of 10 cases.
Topics: Alopecia; Antineoplastic Agents; Busulfan; Cisplatin; Dermis; Diagnosis, Differential; Docetaxel; Etoposide; Female; Hair; Humans; Male; Neoplasms; Taxoids | 2011 |
A novel rat model for chemotherapy-induced alopecia.
Topics: Alopecia; Animals; Antineoplastic Agents; Cyclophosphamide; Disease Models, Animal; Etoposide; Hair Follicle; Rats; Rats, Long-Evans | 2012 |
Low-level laser treatment accelerated hair regrowth in a rat model of chemotherapy-induced alopecia (CIA).
Topics: Alopecia; Animals; Antineoplastic Agents; Cyclophosphamide; Disease Models, Animal; Doxorubicin; Etoposide; Female; Hair; Hair Follicle; Hair Removal; Humans; Low-Level Light Therapy; Male; Mice; Rats; Wound Healing | 2013 |
[Efficacy and survival status of retuximab-NCE regimen treatment in patients with relapsed or refractory B cell non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Fatigue; Female; Follow-Up Studies; Humans; Leukopenia; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Remission Induction; Retrospective Studies; Rituximab; Survival Rate; Thrombocytopenia; Vinblastine; Vinorelbine; Young Adult | 2012 |
Comparison of methotrexate, actinomycin D, and etoposide for treating low-risk gestational trophoblastic neoplasia.
Topics: Adult; Alopecia; Antineoplastic Agents; Chorionic Gonadotropin; Dactinomycin; Etoposide; Female; Gestational Trophoblastic Disease; Humans; Leucovorin; Methotrexate; Nausea; Pregnancy; Prospective Studies; Remission Induction; Stomatitis; Vitamin B Complex; Vomiting; Young Adult | 2012 |
Comparison of vinorelbine, ifosfamide and cisplatin (NIP) and etoposide and cisplatin (EP) for treatment of advanced combined small cell lung cancer (cSCLC) patients: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma; Vinblastine | 2012 |
A soy-derived immunostimulating peptide inhibits etoposide-induced alopecia in neonatal rats.
Topics: Adjuvants, Immunologic; Alopecia; Animals; Etoposide; N-Formylmethionine Leucyl-Phenylalanine; Peptides; Rats; Rats, Sprague-Dawley; Soybean Proteins | 2004 |
FPRL1 receptor agonist peptides prevent etoposide-induced alopecia in neonatal rats.
Topics: Alopecia; Animals; Animals, Newborn; Antineoplastic Agents, Phytogenic; Etoposide; N-Formylmethionine Leucyl-Phenylalanine; Rats; Receptors, Formyl Peptide; Receptors, Lipoxin | 2004 |
Anti-alopecia mechanisms of soymetide-4, an immunostimulating peptide derived from soy beta-conglycinin.
Topics: Adjuvants, Immunologic; Administration, Oral; Alopecia; Animals; Antigens, Plant; Antineoplastic Agents, Phytogenic; Biphenyl Compounds; Cyclooxygenase Inhibitors; Etoposide; Female; Globulins; Histamine H1 Antagonists; Indomethacin; Male; N-Formylmethionine Leucyl-Phenylalanine; NF-kappa B; Peptide Fragments; Prostaglandin-Endoperoxide Synthases; Pyrrolidines; Rats; Receptors, Formyl Peptide; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP4 Subtype; Seed Storage Proteins; Soybean Proteins; Thiocarbamates | 2005 |
Anti-alopecia effect of Gly-Leu-Phe, an immunostimulating peptide derived from alpha-lactalbumin.
Topics: Adjuvants, Immunologic; Alopecia; Animals; Animals, Newborn; Antineoplastic Agents; Etoposide; Lactalbumin; Oligopeptides; Rats | 2005 |
Orally administered FPRL1 receptor agonist peptide MMK-1 inhibits etoposide-induced alopecia by a mechanism different from intraperitoneally administered MMK-1.
Topics: Administration, Oral; Alopecia; Animals; Cimetidine; Disease Models, Animal; Etoposide; Female; Indomethacin; Injections, Intraperitoneal; Male; Peptides; Pyrilamine; Rats; Receptors, Formyl Peptide; Receptors, Lipoxin | 2006 |
Lysocellin, a metabolite of the novel drug 'alopestatin', induces G1 arrest and prevents cytotoxicity induced by etoposide.
Topics: Alopecia; Animals; Animals, Newborn; Antineoplastic Agents, Phytogenic; Area Under Curve; Blotting, Northern; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Down-Regulation; Etoposide; Female; Furans; G1 Phase; Gene Expression; Humans; Male; Osteosarcoma; Proteasome Endopeptidase Complex; Rats; Rats, Sprague-Dawley; RNA, Messenger; Signal Transduction; Up-Regulation | 2006 |
[Efficacy of DICE (dexamethasone, etoposide, ifosfamide, and cisplatin) regimen on recurrent and refractory non-Hodgkin's lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Thrombocytopenia; Young Adult | 2006 |
Mechanism of the protective effect of intraperitoneally administered agonists for formyl peptide receptors against chemotherapy-induced alopecia.
Topics: Alopecia; Animals; Etoposide; Female; Injections, Intraperitoneal; Male; N-Formylmethionine Leucyl-Phenylalanine; Peptides; Rats; Rats, Sprague-Dawley; Receptors, Formyl Peptide | 2007 |
Prevention of chemotherapy-induced alopecia by the anti-death FNK protein.
Topics: Alopecia; Animals; Animals, Newborn; Antineoplastic Agents, Phytogenic; Cell Cycle Proteins; Disease Models, Animal; Dose-Response Relationship, Drug; Etoposide; Hair Follicle; Humans; Injections, Intraperitoneal; Injections, Subcutaneous; Protective Agents; Protein Serine-Threonine Kinases; Rats; Rats, Wistar; Recombinant Fusion Proteins; tat Gene Products, Human Immunodeficiency Virus | 2008 |
Chemotherapy versus chemoimmunotherapy for small-cell undifferentiated carcinoma of the lung.
Topics: Aged; Agranulocytosis; Alopecia; Antineoplastic Agents; BCG Vaccine; Brain Neoplasms; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Prognosis; Prospective Studies; Vomiting | 1980 |
Chemotherapy of refractory germ cell cancer with Etoposide.
Topics: Adolescent; Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Choriocarcinoma; Cisplatin; Dysgerminoma; Etoposide; Humans; Lung Neoplasms; Male; Mesonephroma; Nausea; Neoplasms, Germ Cell and Embryonal; Podophyllotoxin; Retroperitoneal Neoplasms; Testicular Neoplasms | 1983 |
Oral etoposide in gestational trophoblastic disease.
Topics: Adolescent; Adult; Alopecia; Chorionic Gonadotropin; Drug Evaluation; Etoposide; Female; Humans; Middle Aged; Nausea; Parity; Podophyllotoxin; Pregnancy; Trophoblastic Neoplasms; Uterine Neoplasms | 1984 |
VP-16 and adriamycin in patients with advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Fluorouracil; Humans; Leukopenia; Male; Methotrexate; Middle Aged; Podophyllotoxin; Prednisone; Thrombocytopenia; Vincristine; Vomiting | 1982 |
Protection against chemotherapy-induced alopecia by cyclosporin A in the newborn rat animal model.
Topics: Administration, Cutaneous; Alopecia; Animals; Animals, Newborn; Antineoplastic Agents; Cyclophosphamide; Cyclosporine; Cytarabine; Disease Models, Animal; Etoposide; Injections, Intraperitoneal; Rats; Rats, Sprague-Dawley | 1995 |
Oral low-dose etoposide therapy for refractory multiple myeloma with extramedullary involvement.
Topics: Administration, Oral; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Humans; Male; Multiple Myeloma; Prednisolone; Procarbazine; Remission Induction | 1995 |
Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Etoposide; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Pilot Projects; Remission Induction; Sarcoma; Thrombocytopenia | 1996 |
Continuous infusion cisplatin and etoposide chemotherapy for cancer of unknown primary site (CUPS) in Taiwan, a region with a high prevalence of endemic viral infections.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carrier State; Cisplatin; Drug Administration Schedule; Etoposide; Female; Hepatitis B; Hepatitis C; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neoplasms, Unknown Primary; Taiwan; Thrombocytopenia; Virus Diseases | 1998 |
Protection from chemotherapy-induced alopecia by docosahexaenoic acid.
Topics: Alopecia; Animals; Animals, Newborn; Antineoplastic Agents; Apoptosis; Cytarabine; Docosahexaenoic Acids; Etoposide; Female; In Situ Nick-End Labeling; Rats; Rats, Sprague-Dawley | 1999 |
A novel combination of paclitaxel, etoposide, and cyclophosphamide for stem cell mobilization and tumor cytoreduction in ovarian cancer.
Topics: Alopecia; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Transfusion; Carcinoma, Papillary; Cyclophosphamide; Endometrial Neoplasms; Etoposide; Female; Fever; Hematopoietic Stem Cell Mobilization; Humans; Klebsiella Infections; Leukapheresis; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Serous Membrane; Taxoids | 2000 |
Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors.
Topics: Alopecia; Animals; Animals, Newborn; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; CDC2-CDC28 Kinases; Cell Cycle; Cell Line; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; Cyclophosphamide; Cytoprotection; DNA; Doxorubicin; Drug Design; Enzyme Inhibitors; Epithelium; Etoposide; Hair Follicle; Humans; Indoles; Mice; Mice, SCID; Phosphorylation; Protein Serine-Threonine Kinases; Rats; Retinoblastoma Protein; Scalp; Sulfonamides; Transplantation, Heterologous | 2001 |
Cancer research. Preventing hair loss from chemotherapy.
Topics: Alopecia; Animals; Animals, Newborn; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CDC2-CDC28 Kinases; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; Cyclophosphamide; Doxorubicin; Enzyme Inhibitors; Etoposide; Humans; Mice; Protein Serine-Threonine Kinases; Rats | 2001 |
Inhibitory effect of M50054, a novel inhibitor of apoptosis, on anti-Fas-antibody-induced hepatitis and chemotherapy-induced alopecia.
Topics: Alopecia; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase Inhibitors; COS Cells; Cyclohexanones; Enzyme Activation; Etoposide; Fas Ligand Protein; fas Receptor; Female; Hepatitis; Humans; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; U937 Cells | 2001 |
Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents.
Topics: Alkylating Agents; Alopecia; Drug Evaluation; Drug Resistance; Etoposide; Female; Humans; Nausea; Ovarian Neoplasms; Podophyllotoxin; Vomiting | 1978 |
Protection from chemotherapy-induced alopecia by 1,25-dihydroxyvitamin D3.
Topics: Alkylating Agents; Alopecia; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Cyclophosphamide; Doxorubicin; Etoposide; Rats; Rats, Inbred Strains | 1992 |
Combination of etoposide, adriamycin and cisplatin (EAP) in gastric cancer: association with severe toxicity.
Topics: Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Male; Middle Aged; Stomach Neoplasms; Survival Rate; Vascular Diseases | 1991 |
Carboplatin/etoposide as first-line chemotherapy in advanced ovarian carcinoma: a pilot study.
Topics: Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Humans; Leukopenia; Middle Aged; Ovarian Neoplasms; Pilot Projects; Thrombocytopenia; Vomiting | 1991 |
Ifosfamide and mesna in combination with other cytostatic drugs in the treatment of patients with advanced cancer.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Leukopenia; Lung Neoplasms; Male; Mesna; Middle Aged; Nausea; Ovarian Neoplasms; Sarcoma, Ewing; Testicular Neoplasms; Vomiting | 1990 |
Vinblastine, actinomycin D, bleomycin, cyclophosphamide and cis-platinum for advanced germ cell testis tumors: Brazilian experience.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brazil; Chlorambucil; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Administration Schedule; Dysgerminoma; Etoposide; Follow-Up Studies; Humans; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Testicular Neoplasms; Time Factors; Vinblastine; Vomiting | 1985 |
[Adriamycin, cisplatin, and etoposide combination chemotherapy for small cell lung cancer].
Topics: Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Pilot Projects; Remission Induction; Thrombocytopenia | 1989 |
Phase II study with etoposide in previously untreated advanced breast cancer.
Topics: Adult; Aged; Alopecia; Breast Neoplasms; Drug Administration Schedule; Drug Evaluation; Drug Tolerance; Etoposide; Female; Humans; Injections, Intravenous; Leukopenia; Middle Aged; Pilot Projects; Platelet Count; Remission Induction | 1989 |
Oral etoposide preceding cisplatin in advanced non small cell lung cancer (NSCLC). A phase II study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Evaluation; Etoposide; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Prognosis | 1988 |
[A phase II study of NK171 (etoposide)].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Alopecia; Anorexia; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Infusions, Parenteral; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Podophyllotoxin | 1985 |
[A phase II study of etoposide (NK 171) in small cell lung cancer--comparison of results between intravenous administration and oral administration].
Topics: Administration, Oral; Adult; Aged; Alopecia; Anorexia; Carcinoma, Small Cell; Drug Evaluation; Etoposide; Fatigue; Female; Humans; Infusions, Parenteral; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin | 1985 |
[A phase II study of etoposide (VP-16) injection in primary lung cancer by cooperative study group].
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Anorexia; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Injections; Lung Neoplasms; Male; Middle Aged; Nausea; Podophyllotoxin | 1986 |
[A phase II study of intravenous VP-16-213 in small cell and non-small cell carcinoma of the lung].
Topics: Adult; Aged; Alopecia; Carcinoma, Small Cell; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Infusions, Parenteral; Lung Neoplasms; Male; Middle Aged; Nausea; Podophyllotoxin | 1986 |
Methylprednisolone, etoposide, vindesine, and chlorambucil (PEEC) alone or alternating with CHOP as initial or salvage therapy for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Nausea; Prednisone; Prognosis; Remission Induction; Vincristine; Vindesine | 1988 |
A phase I-II study of cytosine arabinoside, daunorubicin, and VP16-213 in adult patients with acute non-lymphocytic leukemia.
Topics: Acute Disease; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Evaluation; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Nausea; Stomatitis; Vomiting | 1986 |
Cisplatin plus etoposide as second-line treatment in advanced ovarian carcinoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Etoposide; Female; Hematologic Diseases; Humans; Middle Aged; Nausea; Neoplasm Staging; Ovarian Neoplasms | 1986 |
[Phase II study of etoposide (VP-16-213) in genitourinary tumors. VP-16-213 Genitourinary Study Group].
Topics: Adult; Aged; Alopecia; Anorexia; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Male; Middle Aged; Nausea; Podophyllotoxin; Prostatic Neoplasms; Testicular Neoplasms; Urinary Bladder Neoplasms; Urogenital Neoplasms | 1986 |
[Phase II study of NK 171 (etoposide) on malignant lymphomas and acute leukemia. A cooperative study group on NK 171 in hematological malignancies].
Topics: Acute Disease; Adolescent; Adult; Aged; Alopecia; Anorexia; Drug Evaluation; Etoposide; Fatigue; Female; Humans; Leukemia; Lymphoma; Male; Middle Aged; Nausea; Podophyllotoxin | 1986 |
[ABEP chemotherapy in the treatment of advanced non-Hodgkin's lymphomas].
Topics: Aclarubicin; Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Leukopenia; Lymphoma; Male; Middle Aged; Naphthacenes; Prednisolone; Thrombocytopenia; Vincristine | 1986 |
[Collaborative phase II study of etoposide (NK-171). Urological Cooperative Study Group of etoposide (NK-171)].
Topics: Administration, Oral; Alopecia; Anorexia; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Infusions, Parenteral; Kidney Neoplasms; Male; Nausea; Podophyllotoxin; Prostatic Neoplasms; Testicular Neoplasms; Urogenital Neoplasms | 1985 |
Phase II study of etoposide (VP-16) in the treatment of advanced head and neck cancer.
Topics: Alopecia; Carcinoma, Squamous Cell; Drug Evaluation; Etoposide; Head and Neck Neoplasms; Humans; Leukopenia; Lymphatic Metastasis; Podophyllotoxin | 1985 |